LY 900014

Drug Profile

LY 900014

Alternative Names: LY-900014

Latest Information Update: 07 Mar 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antihyperglycaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diabetes mellitus; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 23 Feb 2017 Phase-I clinical trials in Type-1 diabetes mellitus (Adjunctive treatment) in Germany (SC) (NCT03056456)
  • 15 Feb 2017 Eli Lilly plans a phase I trial for Type-1 diabetes mellitus (Adjunctive treatment) in Germany (SC) (NCT03056456)
  • 01 Dec 2016 Eli Lilly completes a phase I trial in Healthy volunteers in Singapore (NCT02942654)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top